Calidi Biotherapeutics Inc. Advances Oncolytic Immunotherapy Pipeline with Strategic Focus in 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has made notable strides in its development of systemic oncolytic targeted immunotherapies, as detailed in a recent shareholder letter from CEO Eric Poma, PhD. The letter highlights the company’s transformative year, marked by operational streamlining and advancements in its RedTail platform, a systemically delivered virotherapy […]